1. Biomarkers associated with rapid cartilage loss and bone destruction in osteoarthritis patients. (April 2016) Authors: Arends, R.H.; Karsdal, M.A.; Verburg, K.M.; Bay-Jensen, A.C.; West, C.R.; Keller, D.S. Journal: Osteoarthritis and cartilage Issue: Volume 24(2016)Supplement 1 Page Start: S53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Identification of serological biomarker profiles associated with total joint replacement in osteoarthritis patients. Issue 6 (June 2017) Authors: Arends, R.H.G.P.; Karsdal, M.A.; Verburg, K.M.; West, C.R.; Bay-Jensen, A.C.; Keller, D.S. Journal: Osteoarthritis and cartilage Issue: Volume 25:Issue 6(2017) Page Start: 866 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Postoperative outcome of patients who underwent total joint replacement during the tanezumab phase 3 osteoarthritis development program: a 24-week observational study. Issue 1 (April 2020) Authors: Mont, M.A.; Carrino, J.A.; Shafiei, F.; Nemeth, M.; Burr, A.; Yamabe, T.; Viktrup, L.; West, C.R.; Brown, M.T.; Verburg, K. Journal: Osteoarthritis and cartilage Issue: Volume 28:Issue 1(2020)supplement Page Start: S29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Response to Tanezumab, as assessed by outcome measures in rheumatology-osteoarthritis research society international criteria, in patients with osteoarthritis of the knee or hip. (April 2018) Authors: Schnitzer, T.J.; Bello, A.E.; West, C.R.; Pixton, G.C.; Tive, L. Journal: Osteoarthritis and cartilage Issue: Volume 26(2018)Supplement 1 Page Start: S299 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients. Issue 3 (March 2019) Authors: Karsdal, M.A.; Verburg, K.M.; West, C.R.; Bay-Jensen, A.C.; Keller, D.S.; Arends, R.H.G.P. Journal: Osteoarthritis and cartilage Issue: Volume 27:Issue 3(2019) Page Start: 484 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Standardization of imaging reads for eligibility assessment of patients—component of a risk mitigation strategy in the tanezumab clinical program. (April 2017) Authors: Roemer, F.W.; Miller, C.G.; West, C.R.; Sherlock, S.P.; Brown, M.T.; Kompel, A.J.; Diaz, L.; Galante, N.; Crema, M.D.; Guermazi, A. Journal: Osteoarthritis and cartilage Issue: Volume 25(2017)Supplement 1 Page Start: S415 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks. Issue 1 (April 2020) Authors: Berenbaum, F.; Langford, R.; Perrot, S.; Miki, K.; Blanco, F.J.; Yamabe, T.; Isogawa, N.; Araki, S.; Junor, R.; Carey, W.; Viktrup, L.; West, C.R.; Brown, M.T.; Verburg, K. Journal: Osteoarthritis and cartilage Issue: Volume 28:Issue 1(2020)supplement Page Start: S144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗